Elderly CAncer Patient

NCT ID: NCT02884375

Last Updated: 2016-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The management of older patients with cancer has become a major public health concern in Western countries because of the aging of the population and steady increase in cancer incidence with advancing age. Cancer treatment of aged patients is complex due to comorbidities, polypharmacy and functional status. The heterogeneity of the older population in terms of comorbidities and functional status may explain the difficulty in establishing management recommendations.

Study hypothesis is that a geriatric consultation using Geriatric Assessment (GA) can evaluate patient's resource and strengths, in order to help oncologist to define the most effective treatment. The GA developed by geriatricians and recommended by the International Society of Geriatric Oncology (SIOG), is a multidimensional assessment of general health status; comorbidities; functional status; nutritional, cognitive, psychological, and social parameters; and medications. The GA uses validated geriatric scales to produce an inventory of problems, which can then serve to develop an individualized geriatric intervention plan; it may be an important step in selecting elderly patients for cancer screening and treatment.

The objectives are:

* To assess the role of GA for decision making process for older patients with cancer
* To identify geriatric and oncologic factors associated with overall survival, treatment feasibility, toxicities, morbidities
* To develop and/or validate screening tests for frailty in geriatric oncology
* To develop and validate frailty classifications

Method: The ELCAPA (ELderly CAncer PAtient) survey is a French multicentric prospective study that includes all patients age 70 years or older who has a diagnosis of solid cancer or hematologic malignancies in French hospitals

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Malignancies Solid Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Elderly Cancer Geriatric assessment Treatment Epidemiology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elderly cancer patient cohort

Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)

Extensive GA

Intervention Type OTHER

GA includes an evaluation of nine domains according to international recommendations :

* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))
* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)
* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )
* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)
* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))
* comorbidities (CIRS G)
* polypharmacy (number of medications)
* social environment (primary caregiver, support at home, friends , family, living alone)
* urinary and/or fecal incontinence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extensive GA

GA includes an evaluation of nine domains according to international recommendations :

* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))
* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)
* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )
* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)
* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))
* comorbidities (CIRS G)
* polypharmacy (number of medications)
* social environment (primary caregiver, support at home, friends , family, living alone)
* urinary and/or fecal incontinence

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 70 years or older
* Diagnosed cancer at all stage
* Referred to a geriatrician for GA
* Given oral non-opposition from patient or a legally mandated person

Exclusion Criteria

* Oral opposition
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute, France

OTHER_GOV

Sponsor Role collaborator

Oncogeriatric Coordination Unit (UCOG) - Sud-Val-de-Marne

UNKNOWN

Sponsor Role collaborator

Oncogeriatric Coordination Unit (UCOG) - Paris-Ouest

UNKNOWN

Sponsor Role collaborator

Cancéropôle Ile De France

UNKNOWN

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

PHILIPPE CAILLET, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

ELENA PAILLAUD, MD-PhD

Role: STUDY_DIRECTOR

Assistance Publique - Hôpitaux de Paris

FLORENCE CANOUI-POITRINE, MD-PhD

Role: STUDY_DIRECTOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henri Mondor Hospital

Créteil, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

PHILIPPE CAILLET, MD

Role: CONTACT

Phone: (0)149814707

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Gonzalez Serrano A, Laurent M, Barnay T, Martinez-Tapia C, Audureau E, Boudou-Rouquette P, Aparicio T, Rollot-Trad F, Soubeyran P, Bellera C, Caillet P, Paillaud E, Canoui-Poitrine F. A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis. J Clin Oncol. 2023 Feb 1;41(4):826-834. doi: 10.1200/JCO.22.01118. Epub 2022 Oct 28.

Reference Type DERIVED
PMID: 36306481 (View on PubMed)

Martinez-Tapia C, Diot T, Oubaya N, Paillaud E, Poisson J, Gisselbrecht M, Morisset L, Caillet P, Baudin A, Pamoukdjian F, Broussier A, Bastuji-Garin S, Laurent M, Canoui-Poitrine F. The obesity paradox for mid- and long-term mortality in older cancer patients: a prospective multicenter cohort study. Am J Clin Nutr. 2021 Jan;113(1):129-141. doi: 10.1093/ajcn/nqaa238. Epub 2020 Sep 5.

Reference Type DERIVED
PMID: 32889525 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UG 6729 UCOG

Identifier Type: -

Identifier Source: org_study_id